论文部分内容阅读
目的:分别检测卵巢正常和卵巢良性病变和卵巢癌组织及血清中HK6、B7-H4表达水平,探讨HK6和B7-H4联合诊断卵巢癌的临床意义。方法:免疫组织化学SP法和酶联免疫吸附实验检测卵巢组织及血清中HK6和B7-H4表达水平,并结合临床病理资料分析28例卵巢癌中HK6和B7-H4在组织表达与血清浓度之间相关性。结果:HK6在卵巢癌组织中呈阳性表达,但B7-H4在黏液性癌中呈阴性表达。HK6和B7-H4在卵巢正常患者和卵巢良性病变患者血清中低表达,在卵巢癌患者血清中相对较高表达。卵巢癌患者血清中HK6和B7-H4两种蛋白的表达有明显的正相关关系(P<0.01)。结论:HK6和B7-H4在卵巢癌组织及血清中均较高表达,两者联合可指导卵巢癌诊断。
OBJECTIVE: To detect the expression of HK6 and B7-H4 in normal and benign ovarian lesions, ovarian cancer tissues and serum respectively, and to explore the clinical significance of the combination of HK6 and B7-H4 in the diagnosis of ovarian cancer. Methods: The expressions of HK6 and B7-H4 in ovarian tissue and serum were detected by immunohistochemical SP method and enzyme-linked immunosorbent assay. The expressions of HK6 and B7-H4 in 28 cases of ovarian cancer were analyzed with clinicopathological data. Inter-relatedness. Results: HK6 was positively expressed in ovarian cancer, but B7-H4 was negatively expressed in mucinous carcinoma. HK6 and B7-H4 in ovarian normal patients and benign ovarian lesions in patients with low expression of serum in patients with ovarian cancer is relatively high expression. The serum levels of HK6 and B7-H4 in patients with ovarian cancer showed a significant positive correlation (P <0.01). Conclusions: HK6 and B7-H4 are both highly expressed in ovarian cancer tissues and serum. The combination of both can guide the diagnosis of ovarian cancer.